cancer, leukaemia, ovarian cancer, and uterine cancer. Furthermore, according to the American
Cancer Society, U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the
major cost accounting for around 44%, was paid by private insurance companies.
Increasing incidence of cervical cancer among the global population, rise in incidence of HIV in
women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected to
drive growth of the cervical cancer drugs market. Moreover, American cancer Society, in March
2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million.
The funding value is offered to a single or group of research, which includes a specific type of a
cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data findings,
around 3,200 new cervical cancer cases were registered in the UK annually from 2013 to 2015.
Moreover, according to the same source, in 2015, cervical cancer accounted for around 2% of all
cancer cases in females in the UK. A joint study conducted on cervical cancer by the Associated
Chambers of Commerce and Industry of India (ASSOCHAM) and National Institute of Cancer
Prevention and Research (NICPR), published in January 2018, reported that India alone has one
fourth of the global burden of cervical cancer, which accounts for 17% of the all cancer deaths in
women aged between 30 and 69 years in India. Moreover, according to the same source, it is
estimated that around 1 in 53 Indian women are expected to be diagnosed by cervical cancer during
their lifetime.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cervical-
cancer-drugs-market-1746
Cervical Cancer Drugs Market - Regional Analysis
Geographically, cervical cancer drugs market is segmented into North America, Latin America,
Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in cervical
cancer drugs market, owing to increasing incidences of cervical cancer and growing research and
development activities by various healthcare regulatory organizations in these region. For instance,
according to the American Cancer Society’s (ACS) estimates for cervical cancer in the U.S. for
2018, around 13, 240 new cases of invasive cervical cancer were diagnosed and around 4,170
women are expected to die from cervical cancer. For instance, in 2013, Cervical Cancer-Free
Coalition (CCFC) announced a collaborative research projects with funds ranging from US$ 5,000-
US $10,000 each, which are focused on cervical cancer treatment in the U.S.
Cervical Cancer Drugs Market Competitive Landscape
Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La
Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc.,
Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and
Novartis AG. Key players operating in the market are focused on organic growth strategies, in order
to enhance its market share and retain its competence in the market. For instance, in July 2014,
MedImmune: a biologics research and development division of AstraZeneca entered into a clinical
trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II
immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-
L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy
vaccine: ADXS-HPV. These study is conducted to develop treatment for patients with advanced,
recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.
Cervical Cancer Drugs Market Taxonomy:
By Cancer Type:
•Squamous Cell Cancer